Everything below concerns 双受体激动. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Also, the Penning trap can be made larger whilst maintaining strong trapping. The trapped ion can then be held further away from the electrode surfaces. Interaction with patch potentials on the electrode surfaces can be responsible for heating and decoherence effects and these effects scale as a high power of the inverse distance between the ion and the electrode.
== History == Dimethocaine was originally synthesized by the Hoffmann-La Roche company in 1930. It was sold under the market name larocaine. During the 1930s dimethocaine gained popularity in the US as a local anesthetic. Just like cocaine and procaine, it was used during surgery, primarily in dentistry, ophthalmology and otolaryngology. However, in the 1940s, it was removed from the market because of its psychoactive effects and risk of addiction. Nowadays dimethocaine is abused for these psychoactive effects. It is sold as a cocaine surrogate to circumvent legislation issues.
=== Positions of employment === 1982-1985 Instructor and assistant. Associate Professor, University of Copenhagen 1986-1987 Clinical Department Ph.D. scholarship, University of Copenhagen 1987-1988 Department of Pharmacology Ph.D. scholarship, University of Copenhagen 1988 - 1991 Pharmacologist at LEO Pharma 1991 - 2000 Management positions at Novo Nordisk, from 1994 as research director 1991 – 1993 Head of growth hormone pharmacology, Biopharmaceuticals Division, Novo Nordisk 1993 – 1994 Director of pharmacology, Diabetes Care Division, Novo Nordisk 1994 – 1995 Senior vice president of diabetes research & development, Diabetes Care Division, Novo Nordisk 1995 – 1998 Corporate vice president of Drug Discovery, Novo Nordisk 1998 – 2000 Corporate vice president of drug discovery and preclinical development, Novo Nordisk 2000 – 2021 Group vice president of research and development, Novo Nordisk 2000 – adjunct professor of pharmacology, University of Copenhagen 2021 - CEO, Novo Nordisk Foundation
Liquid chromatography–mass spectrometry (LC–MS) is an analytical chemistry technique that combines the physical separation capabilities of liquid chromatography (or HPLC) with the mass analysis capabilities of mass spectrometry (MS). Coupled chromatography–MS systems are popular in chemical analysis because the individual capabilities of each technique are enhanced synergistically. While liquid chromatography separates mixtures with multiple components, mass spectrometry provides spectral information that may help to identify (or confirm the suspected identity of) each separated component. MS is not only sensitive, but provides selective detection, relieving the need for complete chromatographic separation. LC–MS is also appropriate for metabolomics because of its good coverage of a wide range of chemicals. This tandem technique can be used to analyze biochemical, organic, and inorganic compounds commonly found in complex samples of environmental and biological origin. Therefore, LC–MS may be applied in a wide range of sectors including biotechnology, environment monitoring, food processing, and pharmaceutical, agrochemical, and cosmetic industries. Since the early 2000s, LC–MS (or more specifically LC–MS/MS) has also begun to be used in clinical applications. In addition to the liquid chromatography and mass spectrometry devices, an LC–MS system contains an interface that efficiently transfers the separated components from the LC column into the MS ion source. The interface is necessary because the LC and MS devices are fundamentally incompatible.
== Discovery == Factor XIII Deficiency is also known as Laki–Lorand factor, after Kalman Laki and Laszlo Lorand, the scientists who first proposed its existence in 1948. A 2005 conference recommended standardization of nomenclature.
Sources: en.wikipedia.org
Ion exchange chromatography can be used to separate proteins because they contain charged functional groups. The ions of interest (in this case charged proteins) are exchanged for another ions (usually H+) on a charged solid support. The solutes are most commonly in a liquid phase, which tends to be water. Take for example proteins in water, which would be a liquid phase that is passed through a column. The column is commonly known as the solid phase since it is filled with porous synthetic particles that are of a particular charge. These porous particles are also referred to as beads, may be aminated (containing amino groups) or have metal ions in order to have a charge. The column can be prepared using porous polymers, for macromolecules of a mass of over 100 000 Da, the optimum size of the porous particle is about 1 μm2. This is because slow diffusion of the solutes within the pores does not restrict the separation quality. The beads containing positively charged groups, which attract the negatively charged proteins, are commonly referred to as anion exchange resins. The amino acids that have negatively charged side chains at pH 7 (pH of water) are glutamate and aspartate. The beads that are negatively charged are called cation exchange resins, as positively charged proteins will be attracted. The amino acids that have positively charged side chains at pH 7 are lysine, histidine and arginine. The isoelectric point is the pH at which a compound—in this case a protein—has no net charge.
Field ration – a field ration, combat ration or ration pack is a canned or pre-packaged meal, easily prepared and eaten, transported by military troops on the battlefield. Humanitarian daily ration Individual Meal Pack Meal, Ready-to-Eat Military rations
Mendelian randomization is a method in genetic epidemiology that seeks to identify causal relationships between risk factors and diseases. It uses the randomness of inheriting different genes to do so. Using Mendelian randomization, it was found that PMOS has causal links to sex hormone-binding globulin level, anti-Müllerian hormone (AMH) level, menopause age, body fat percentage, insulin resistance, depression, breast cancer, ovarian cancer, obsessive-compulsive disorder, and lung capacity. Other factors do not seem causally linked: anxiety disorder, schizophrenia, type 2 diabetes, coronary heart disease, stroke, or birth weight.
== Patents == Penicillin patents became a matter of concern and conflict. Chain had wanted to apply for a patent but Florey had objected, arguing that penicillin should benefit all. Florey sought the advice of Sir Henry Dale, the chairman of the Wellcome Trust and a member of the Scientific Advisory Panel to the British Cabinet, and John William Trevan, the director of the Wellcome Trust Research Laboratory. On 26 and 27 March 1941, Dale and Trevan met at Oxford University's Sir William Dunn School of Pathology to discuss the issue. Dale advised that patenting penicillin would be unethical. Undeterred, Chain approached Sir Edward Mellanby, then Secretary of the Medical Research Council, who also objected on ethical grounds. As Chain later admitted, he had "many bitter fights" with Mellanby, but Mellanby's decision was accepted as final.
Petrov underwent intense questioning by his superiors about his actions. Initially, he was praised for his decision. General Yuri Votintsev, then commander of the Soviet Air Defense's Missile Defense Units, who was the first to hear Petrov's report of the incident (and the first to reveal it to the public in 1998), stated that Petrov's "correct actions" were "duly noted". Petrov himself stated he was initially praised by Votintsev and was promised a reward, but recalled that he was also reprimanded for improper filing of paperwork with the pretext that he had not described the incident in the military diary. He received no reward. According to Petrov, this was because the incident and other bugs found in the missile detection system embarrassed his superiors and the influential scientists who were responsible for it, so that if he had been officially rewarded, they would have had to be punished. He was reassigned to a less sensitive post, took early retirement (although he emphasized that he was not "forced out" of the army, as is sometimes claimed by Western sources), and suffered a nervous breakdown. Oleg Kalugin, a former KGB chief of foreign counter-intelligence who knew Soviet leader Yuri Andropov well, said that Andropov's distrust of American leaders was profound. It was conceivable that if Petrov had declared the satellite warnings valid, such an erroneous report could have provoked the Soviet leadership into becoming bellicose. Kalugin said: "The danger was in the Soviet leadership thinking, 'The Americans may attack, so we better attack first.'"
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。